Tempus AI expanded its AI-enabled 'Next' platform to deliver real-time clinical intelligence for oncology.
The update introduces capabilities for six new clinical scenarios. These scenarios cover breast, colorectal, ovarian, and prostate cancers.
The platform analyzes unstructured electronic health record data to close care gaps, map patient journeys, and address care disparities.
Ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Tempus highlighted a study demonstrating the platform's impact.
The study showed the system increased guideline-recommended biomarker testing rates for non-small cell lung cancer patients. This increase led to optimized therapy management.